BUZZ BOMB™ captures over 400,000 views and a spike in online revenue driven by strategic brand expansion and Ashley Paulson’s historic record at the Jackpot Ultra Running Festival.
ESTERO, FL / ACCESS Newswire / February 25, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (“Aspire” or the “Company”), today announced a massive expansion of its social media and digital marketing footprint for its wholly owned subsidiary, Buzz Bomb Caffeine Company. The initiative follows a successful strategic rebranding and a high-profile sponsorship of professional ultra-marathoner Ashley Paulson, whose recent world-record performance catalyzed a significant increase in brand visibility and consumer acquisition.
BUZZ BOMB™-a caffeine supplement delivering a precise 50mg serving in convenient and flavorful stick packs-has seen its social media content surpass 400,000 views in a 48-hour period after the race. This digital momentum coincides with the brand’s recent evolution, featuring a sleek modern website and science-forward packaging designed to appeal to high-performance athletes and everyday consumers alike.
The brand’s visibility reached a fever pitch at the 2026 Jackpot Ultra Running Festival. BUZZ BOMB™ Brand Ambassador Ashley Paulson set a new women’s world record during the USATF 100-Mile Road Championship, winning the event by over two hours with a staggering time of 12:19:34 (breaking the old record by more than 20 minutes). Competing in her signature pink ponytail and BUZZ BOMB™ gear, Paulson credited her use of BUZZ BOMB™ caffeine supplements for helping her maintain her 7:21 per mile pace throughout the 100-mile race. Ashley’s accomplishments were highlighted in Runner’s World and on the US Track and Field web sites. Runner’s World featured an article about Ashley’s record.
“We are thrilled that our brand ambassador, Ashley Paulson, achieved a first-place finish for women at the Jackpot Ultra Running Festival,” said Kraig Higginson, Interim CEO of Aspire Biopharma. “We didn’t just want a face for the brand; we wanted an elite athlete who relies on our caffeine products to perform at the highest level possible. Ashley’s world record-breaking win supports our belief that BUZZ BOMB™ is the ultimate tool for sustained performance.”
Buzz Bomb Caffeine Company team members were there to cheer Ashley and in a post-race interview with her sponsor, she said, “Honestly, it doesn’t feel real. I’m like, has this really happened? … I worked so hard for it, but it came, it happened. Dreams come true, you just got to keep fighting for it and show up, put in the work, and then execute.”
For more about Ashley Paulson, follow her on Instagram, TikTok and Facebook.
https://www.instagram.com/ashkickn/?hl=en,
https://www.tiktok.com/@ashkickn1
https://www.facebook.com/ashley.j.paulson/
BUZZ BOMB™ Caffeine Products
Unlike traditional energy drinks or pills, BUZZ BOMB™ is a new and exciting caffeine product delivered in a single-serving stick pack of dry powder sprinkled under the tongue. This method provides flavored caffeine quickly without the hassle of mixing with water or consuming typical caffeine sources like energy drinks, coffee, or soda.
BUZZ BOMB™ features 50mg of caffeine and is currently offered in four delicious flavors: Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha. Designed for athletes, professionals, and the everyday person needing a rapid boost, BUZZ BOMB™ provides a precise serving of caffeine in easy-to-use single serving stick packs.
To learn more about BUZZ BOMB™, or purchase product online, please visit https://buzzbombcaffeine.com or follows us on social media here:
About Aspire Biopharma Holdings, Inc.
Aspire Biopharma delivers supplements to the body rapidly and precisely.
For more information, please visit www.aspirebiolabs.com
Aspire Biopharma Holdings, Inc.
Contact
PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.com
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by those laws. Aspire’s forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ in our drug or supplement offerings include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug or supplement candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our product candidates, and other risks and uncertainties set forth in “Risk Factors” in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.
SOURCE: Aspire Biopharma Holdings, Inc.
View the original press release on ACCESS Newswire
